Industry news
-
Patient Influencers Trust Social Media Groups More than Pharma Websites
18 April 2019
Patient influencers trust social media groups more than pharma websites for health information, according to a survey from Wego Health. These influencers are most likely to turn to groups on Facebook, Instagram and Twitter as their first source for health information, followed by health websites such as WebMD, patient advocacy organization portals, their doctor, patient blogs and YouTube. Only 3% said they prefer pharma websites.
-
Big spending from AbbVie, Pfizer pushes pharma's 2018 ad spend to $6.5B
18 April 2019
Pharmaceutical ad spending continued its upward climb last year. Spending topped $6.46 billion in 2018, according to Kantar Media, for an increase of 4.8% over the previous year.
-
Russia Pharma Market Grew by 2.6%
17 April 2019
The volume of the Russian pharmaceutical market in 2018 increased by 2.6% reaching 1.68 trillion rubles, follows from the annual report of DSM Group, cited by RIA Novosti. In real terms, drug sales increased by 1.5% and totalled 6.4 billion packs.
-
Russia Fights with False Information in Medicine Monitoring System
17 April 2019
The State Duma adopted in a final third reading on Tuesday (April 9) a bill on fines for untimely entry or import of false information into the medicinal drugs monitoring system. Under the bill, officials would face fines from 5,000 to 10,000 rubles ($80 – $160), companies would be punished with fines ranging from 50,000 to 100,000 rubles ($800 – $1,600) for such offenses.
-
Nobel Laureate is Demanding More Money from Ono Pharma for Cancer Drug
16 April 2019
Nobel laureate Tasuku Honjo said Wednesday he is involved in a dispute over license fees under a patent agreement with Ono Pharmaceutical Co., which sells a cancer treatment drug developed based on his research.
-
Russian Drug Maker Gains World’s First Approval for Biosimilar Eculizumab
15 April 2019
Russian drug manufacturer Generium Pharmaceutical, which specializes in orphan drugs, announced yesterday that it has received Russian marketing approval for its biosimilar eculizumab, referencing Soliris, the most expensive orphan drug in Russia.
-
Method of Price Registration in Russia
15 April 2019
The state policy on medicine and medical products circulation was discussed at the XI All-Russian Congress of the Pharmaceutical and Medical Industries. “Unfortunately, current trend is to tie all issues in the pharmaceutical industry with regulating medical prices”, started her speech Deputy Head of FAS Department for Control over Social Sphere and Trade, Nadezhda Sharavskaya. She pointed out that “competences of the pharmaceutical companies are formed today based on the artificial media hype rather than the valid and the RIA projects”.
-
aunching of Russian Vaccines in Latin America
12 April 2019
MECHNIKOV Institute has launched the production of commercial vaccine batches in Managua (Nicaragua). The launch of the production lines was attended by the advisor for investments of the Government of Nicaragua Laureano Ortega, Deputy Minister of Health of the Russian Federation Sergey Kraevoy, President of the Nicaraguan Institute of Social Insurance Dr. Roberto Lopez, Head of Federal medical and biological agency of Russia (FMBA) Viktor Uiba and Director of the Saint-Petersburg scientific research institute of vaccines and serums of the FMBA of Russia (SPbSRIVS) Viktor Trukhin. The project has been implemented pursuant to the Instruction of Vladimir Putin, the President of the Russian Federation.
-
New Track-and-Trace System in Russia
12 April 2019
Christoph Krähenbühl, senior director of Excellis Europe, explains the challenge the new Russian traceability regulations present to the pharma industry, and how all participants in the supply chain must properly prepare to ensure that they become compliant within this new environment.
-
Diabetic foot treatment supported
11 April 2019
Russia’s Skolkovo Foundation and Human Stem Cells Institute (HSCI), a private holding company, are supporting a young Russian company called NextGene, a Skolkovo resident. Of the $492,000 grant funding, an estimated $246,000 should come from Skolkovo and HSCI is expected to match the amount, the Skolkovo Foundation website announced .
